Understanding HbA1c Assay Performance
Learn how assay bias and imprecision can affect HbA1c results and influence the diagnosis and monitoring of diabetes.
Performance of HbA1c Assays in relation to clinical requirements for its use in diabetes
HbA1c is a major test in the medical laboratory because the test result is of conclusive relevance for diagnosis and treatment of diabetes, a high prevalence chronic disease. Therefore, the quality of the test is of utmost clinical importance. The impact of bias and imprecision will be discussed and requirements for diagnosis and monitoring treatment be derived from the IFCC model for quality targets.
To demonstrate the present status of HbA1c tests, the outcome of EurA1c and the international PT trial with participation of more than 5000 labs in 20 countries will be shown.
This webinar is presented in English.
What will you learn?
Applying IFCC Quality Targets in Clinical Practice
Discover the quality requirements for HbA1c testing based on the IFCC model and their importance for reliable patient care.
Insights from Global HbA1c Quality Assessment Programs
Explore results from the EurA1c study and an international proficiency testing program involving more than 5,000 laboratories, highlighting the current performance of HbA1c assays worldwide.
Accurate detection of HbA1c is very important for diagnosis even more than for monitoring
About Dr. Cas WEYKAMP
Dr. Cas Weykamp is a Clinical Chemist and former Director of the MCA Laboratory at Queen Beatrix Hospital in Winterswijk, the Netherlands.
A recognized expert in HbA1c standardization, he served as Network Coordinator of the worldwide network of 16 reference laboratories operating the IFCC reference method for HbA1c and was a member of the IFCC Committee on Education and Use of Biomarkers in Diabetes. He is also an advisor to the National Glycohemoglobin Standardization Program (NGSP) and has worked extensively on the harmonization, standardization, and external quality assessment (EQA) of laboratory testing.
In the Netherlands, Dr. Weykamp coordinates several EQA programs on behalf of SKML, including a major HbA1c scheme that formed the basis of his PhD research. He has also contributed to numerous international initiatives through the IFCC and AACC, focusing on proficiency testing, commutability, harmonization, and clinical laboratory quality improvement. A frequent speaker at international scientific meetings, Dr. Weykamp has authored numerous publications in the field of laboratory medicine and diabetes diagnostics.
Test associated with this resource
Deepen your expertise with additional webinars
Comprehensive data analysis and interpretation software for Sebia assays on Electrophoresis instruments.
Educational Webinar with M. Jean Deenmamode, IFCC Working Group Chair
Educational Webinar with Gerd-Rüdiger Burmester, MD & Roberto Fiorillo
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.